News Releases

 
News Releases
  Date Title and Summary View
Mar 15, 2004
March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest Laboratories, Inc. (NYSE: FRX) announced today that the two companies have entered into a collaboration agreement to develop and commercialize novel small molecule therapeutics for autoimmune and inflammator...
Jan 13, 2004
January 13, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has initiated a Phase I clinical trial to evaluate its novel drug candidate for the treatment of inflammatory bowel disease (IBD). The compound, known as Traficet-EN™, is a novel, orally active anti-inflammatory agent that targets a chem...
Oct 13, 2003
October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company a $14 million grant to develop first-in-class immune modulatory agents targeting chemokine receptors for the prevention and ...
Sep 17, 2002
September 17, 2002; San Carlos, Calif. — ChemoCentryx, Inc. today announced the initiation of a Phase I clinical trial in the United Kingdom by its partner, Tularik Inc., (Nasdaq: TLRK), for T487, an oral anti-inflammatory drug candidate. T487 is the most advanced clinical candidate in ChemoCentryx's broad pipeline ...
Page: FirstPrevious ...
19
= add release to Briefcase